Regarding the mechanism by which TANs kill antibody-activated tumor cells, current preclinical evidence suggests that neutrophil-mediated ADCC can be increased by blocking the CD47-SIRPα axis, increasing the efficacy of antibodies targeting tumors.129 At present, several antibodies or therapeutic biological agents targeting CD47 or SIRPα have been developed in clinical settings. This evidence concerns the gene SIRPA and neoplasm.